e-Drug3D

2189

SONROTOCLAX

INN
SONROTOCLAX

cas 2383086-06-2

CLASS

ANTINEOPLASTIC
BCL-2 INHIBITOR
TREATMENT OF MANTLE CELL LYMPHOMA (MCL)

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 4 HOUR
VD 482 LITER
Cl 94 LITER / HOUR
PPB 99 PERCENT
t1/2 5 HOUR

Target

TARGET BCL-2

PDB
8HOG (CRYSTAL STRUCTURE OF BCL-2 IN COMPLEX WITH SONROTOCLAX)

Ligand code = 98I (link to the list of PDB complexes)

Download experimental 3D coordinates of 98I with added hydrogens

DrugCentral

Download SDF file

Benzamide, N-[[4-[[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2S)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-

Formula:
C49H59N7O7S

Calculated chemical properties:

MW 890.10
NB_atoms 64
XLogP 9.44
PSA 171.783
NB_HD 4
NB_HA 13
fsp3 0.47
Lipinski(0=no;1=yes) 0

FDA
NDA 220711 (label) INN (SONROTOCLAX) BEQALZI (BEONE MEDICINES USA) APPROVAL= AP YEAR= 2026 NEWMOLECULARENTITY